Glycol Salicylate
Active ingredient
Sold as NEW AMMELTZ
- Drug class
- -
- Availability
- See label
- Routes
- Topical
- Markets covered
- 2
- Products on record
- 2
Overview
Glycol Salicylate is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | September 5, 2025 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
GBUnited Kingdom· MHRA
1 product
Uses
External application for the symptomatic treatment of muscle stiffness, muscular rheumatism, lumbago, sciatica, fibrositis, sprains and chilblains.
How to take
Apply externally with gentle massage 2 - 3 times daily, avoiding broken or inflamed skin. DO NOT APPLY TO CHILDREN UNDER 6 YEARS OF AGE.
This is not medical advice. Consult a qualified healthcare professional.
Side effects & warnings
Photosensitivity and application site reactions. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for ‘MHRA Yellow Card’ in the Google Play or Apple App Store.
Do not apply to broken or tender skin. Application on mucous membranes should be avoided. Discontinue if rash develops. Not for use with occlusive dressings. Topical application may result in systemic effects, including asthma. Patients should be advised against excessive exposure of areas treated to sunlight, in order to avoid possibility of photosensitivity.
Keep away from eyes. Wash hands after use.
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
3. Contra-indications Known sensitivity to any of the ingredients. Do not apply to children less than six years old.
This is not medical advice. Consult a qualified healthcare professional.
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Brands in Canada (1)
Sources & citations
- [1]MHRA (UK) · PL003865007 · revised September 5, 2025
- [2]Health Canada (DPD) · 02322714 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.